

Leiping Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2684364/publications.pdf>

Version: 2024-02-01

40
papers

716
citations

567281

15
h-index

580821

25
g-index

40
all docs

40
docs citations

40
times ranked

1421
citing authors

#	ARTICLE	IF	CITATIONS
1	PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. <i>BMC Cancer</i> , 2011, 11, 248.	2.6	135
2	Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer. <i>BMC Cancer</i> , 2018, 18, 446.	2.6	74
3	Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 U/L. <i>Tumor Biology</i> , 2016, 37, 14083-14088.	1.8	50
4	A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer. <i>Oncotarget</i> , 2017, 8, 84224-84236.	1.8	47
5	Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy. <i>Oncotarget</i> , 2015, 6, 43135-43143.	1.8	36
6	Depletion of SENP1 suppresses the proliferation and invasion of triple-negative breast cancer cells. <i>Oncology Reports</i> , 2016, 36, 2071-2078.	2.6	31
7	A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel. <i>Scientific Reports</i> , 2017, 7, 6584.	3.3	30
8	Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer. <i>Cell Death and Disease</i> , 2021, 12, 684.	6.3	27
9	Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis. <i>Cancer Research and Treatment</i> , 2020, 52, 1059-1066.	3.0	26
10	miR-331-3p Suppresses Cell Proliferation in TNBC Cells by Downregulating NRP2. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382090582.	1.9	22
11	Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 389-399.	2.5	21
12	An explorative analysis of the prognostic value of lactate dehydrogenase for survival and the chemotherapeutic response in patients with advanced triple-negative breast cancer. <i>Oncotarget</i> , 2018, 9, 10714-10722.	1.8	20
13	Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer. <i>International Journal of Nanomedicine</i> , 2014, 9, 1443.	6.7	19
14	Apatinib for metastatic breast cancer in non-clinical trial setting: Satisfying efficacy regardless of previous anti-angiogenic treatment. <i>Tumor Biology</i> , 2017, 39, 101042831771103.	1.8	19
15	Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial. <i>BMC Cancer</i> , 2018, 18, 1019.	2.6	19
16	Phase II study of chidamide in combination with cisplatin in patients with metastatic triple-negative breast cancer. <i>Annals of Palliative Medicine</i> , 2021, 10, 11255-11264.	1.2	13
17	Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial. <i>Investigational New Drugs</i> , 2020, 38, 507-514.	2.6	12
18	GSTT1, GSTP1, and GSTM1 genetic variants are associated with survival in previously untreated metastatic breast cancer. <i>Oncotarget</i> , 2017, 8, 105905-105914.	1.8	12

#	ARTICLE	IF	CITATIONS
19	Phase II Study of <i>Pseudomonas aeruginosa</i> -Mannose-Sensitive Hemagglutinin in Combination with Capecitabine for Her-2â€“Negative Metastatic Breast Cancer Pretreated with Anthracycline and Taxane. <i>PLoS ONE</i> , 2015, 10, e0118607.	2.5	11
20	Efficacy and safety of mitoxantrone hydrochloride liposome injection in Chinese patients with advanced breast cancer: a randomized, open-label, active-controlled, single-center, phase II clinical trial. <i>Investigational New Drugs</i> , 2022, 40, 330-339.	2.6	10
21	A retrospective analysis of outcomes for primary mediastinal large B-cell lymphoma treated with RCHOP followed by radiotherapy or front-line autologous stem cell transplantation. <i>Hematology</i> , 2017, 22, 258-264.	1.5	8
22	Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China. <i>Medical Science Monitor</i> , 2020, 26, e927187.	1.1	8
23	Dalpiciclib Combined With Pyrotinib and Letrozole in Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer (LORDSHIPS): A Phase Ib Study. <i>Frontiers in Oncology</i> , 2022, 12, 775081.	2.8	8
24	Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial. <i>PLoS ONE</i> , 2015, 10, e0133133.	2.5	7
25	PDGFD induces ibrutinib resistance of diffuse large Bâ€“cell lymphoma through activation of EGFR. <i>Molecular Medicine Reports</i> , 2020, 21, 2209-2219.	2.4	7
26	Everolimus-Related Pneumonitis in Patients with Metastatic Breast Cancer: Incidence, Radiographic Patterns, and Relevance to Clinical Outcome. <i>Oncologist</i> , 2021, 26, e580-e587.	3.7	7
27	Thalidomide enhanced the efficacy of CHOP chemotherapy in the treatment of diffuse large B cell lymphoma: A phase II study. <i>Oncotarget</i> , 2016, 7, 33331-33339.	1.8	6
28	Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study. <i>Clinical Breast Cancer</i> , 2019, 19, e452-e458.	2.4	5
29	Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer. <i>Scientific Reports</i> , 2019, 9, 3563.	3.3	4
30	Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study. <i>Scientific Reports</i> , 2019, 9, 1710.	3.3	4
31	Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a realâ€“world study for patients with hormone receptorâ€“positive and HER2â€“negative advanced breast cancer. <i>Cancer Medicine</i> , 2020, 9, 8821-8831.	2.8	4
32	Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China. <i>Medical Science Monitor</i> , 2020, 26, e927187.	1.1	4
33	Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 719-726.	2.5	3
34	<p>Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience</p>. <i>Therapeutics and Clinical Risk Management</i> , 2020, Volume 16, 607-615.	2.0	3
35	Whether low-dose metronomic oral cyclophosphamide improves the response to docetaxel in first-line treatment of non-triple-negative metastatic breast cancer. <i>Oncotarget</i> , 2017, 8, 79527-79536.	1.8	2
36	Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor SHR6390 combined with pyrotinib and letrozole in patients with human epidermal growth factor receptor 2-positive (HER2+), hormone receptor positive (HR+) metastatic breast cancer (MBC): Phase Ib study results.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1035-1035.	1.6	1

#	ARTICLE	IF	CITATIONS
37	Phase II trial of nab-paclitaxel in metastatic breast cancer patients with visceral metastases. BMC Cancer, 2021, 21, 1174.	2.6	1
38	An integrated bioinformatics analysis to investigate the targets of miR-133a-1 in breast cancer. Translational Cancer Research, 2021, 10, 1238-1248.	1.0	0
39	Pretreatment 18F-FDG uptake heterogeneity predicts response to pyrotinib in patients with metastatic HER2-positive breast cancer.. Journal of Clinical Oncology, 2021, 39, e15026-e15026.	1.6	0
40	Apatinib plus vinorelbine versus vinorelbine for advanced triple-negative breast cancer with failed first or second-line treatment: The NAN trial.. Journal of Clinical Oncology, 2021, 39, 1075-1075.	1.6	0